Vaccinex raises $9.7M in private placement of 8.75M shares at $1.11; January equity total $13.2M

VACCINEX, INC.

Private placement closed Jan 31 with 8,747,744 shares at $1.11/share; gross proceeds ~$9.7M after amendment adding 2.8M shares.
Affiliated investors include CEO Maurice Zauderer ($2M), Chairman Albert Friedberg ($2M), and director Jacob Frieberg.
Additional $3.5M raised via ATM sales earlier in January at weighted avg $1.16/share, bringing month total to ~$13.2M.
Proceeds will fund development of lead drug candidate pepinemab in cancer and neurodegenerative disease.
Registration rights agreement requires filing resale shelf within 75 days; failure triggers liquidated damages.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.